pubmed.ncbi.nlm.nih.gov

Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial - PubMed

Randomized Controlled Trial

Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial

D D Gladman et al. Ann Rheum Dis. 2007 Feb.

Abstract

Objective: To evaluate the effects of adalimumab on patient-reported outcomes of joint-related and skin-related functional impairment, health-related quality of life, fatigue and pain in patients with psoriatic arthritis (PsA).

Methods: Patients with moderately- to severely- active PsA were treated with adalimumab, 40 mg, every other week, or placebo, in this 24-week, randomised, controlled trial. Patient-reported outcomes included the Health Assessment Questionnaire Disability Index (HAQ DI), Short-Form 36 Health Survey (SF-36), the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale and the Dermatology Life Quality Index (DLQI).

Results: Adalimumab (n = 151) and placebo (n = 162) groups were comparable with respect to baseline demographics and disease severity. Significant changes from baseline in HAQ DI were reported for adalimumab v placebo (-0.4 v -0.1, p<0.001) at both 12 and 24 weeks. At week 24, significant improvements in the SF-36 domains of physical functioning, role-physical, bodily pain, general health, vitality and social functioning, as well as the physical component summary score, were observed for adalimumab versus placebo (p<0.01). These reported changes in HAQ DI and SF-36 were also clinically important. Significantly more patients treated with adalimumab had complete resolution of functional loss (HAQ DI = 0) and dermatological-related functional limitations (DLQI = 0) compared with placebo at weeks 12 and 24 (p< or =0.001). Adalimumab led to significantly greater improvements in FACIT-Fatigue scores, pain scores, and disease activity measures versus placebo at 12 and 24 weeks (p<0.001 for all).

Conclusions: Adalimumab improved physical-related and dermatological-related functional limitations, HRQOL, fatigue and pain in patients with PsA treated for 24 weeks.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

Similar articles

Cited by

References

    1. Mease P J. Tumor necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 200261298–304. - PMC - PubMed
    1. Winterfield L S, Meneter A, Gordon K, Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 20056487–90. - PMC - PubMed
    1. Gladman D D. Quality of life: psoriatic arthritis. In: Gordon KB, Ruderman EM, eds. Psoriasis and psoriatic arthritis: an integrated approach. Heidelberg, Germany: Springer, 2004118–123.
    1. Gladman D D, Shuckett R, Russell M L, Thorne J C, Schachter R K. Psoriatic arthritis (PsA) ― an analysis of 220 patients. QJM 198762127–141. - PubMed
    1. Hahn H B, Melfi C A, Chuang T Y, Lewis C W, Gonin R, Hanna M P.et al Use of the Dermatology Life Quality Index (DLQI) in a Midwestern US urban clinic. J Am Acad Dermatol 20014544–48. - PubMed

Publication types

MeSH terms

Substances